Pigache 1973.

Methods	Allocation: randomly assigned, pairs matched on clinical status and IQ, cross‐over design. Blinding: double, independent pharmacist, sealed in individual envelopes. Duration: 55 weeks (preceded by 3 months stabilisation on chlorpromazine).
Participants	Diagnosis: schizophrenia. N=20. Age: 30‐50 yrs. Sex: all males. History: chronic> 2 yrs, unmarried. Excluded: given ECT or Insulin therapy during the last 12 months, physically unwell. Setting: hospital.
Interventions	1. Chlorpromazine cessation: placebo. N=10. 2. Chlorpromazine continuation: dose 50‐100 mg/day. N=10. Minor analgesics, antibiotics (as necessary).
Outcomes	Relapse. Mental state: BPRS, PAT. Leaving the study early (cross over design: 2 patients; placebo at the time of leaving. 1 patient; CPZ 50% at the time of leaving). Unable to use ‐ Biochemistry: Blood + urine tests (no data). Global state: Average Global Rating Scale (no SD).
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	B ‐ Unclear